• Amyloid-Like Rapid Surface Modification for Antifouling and In-Depth Remineralization of Dentine Tubules to Treat Dental Hypersensitivity
    Amyloid-Like Rapid Surface Modification for Antifouling and In-Depth Remineralization of Dentine Tubules to Treat Dental Hypersensitivity January 6,2020.
    Exposure of dentinal tubules (DTs) leads to the transmission of external stimuli within the DTs, causing dental hypersensitivity (DH). Approximately 42% 18- to 35-year-olds experience dental hypersensitivity (DH), which is characterized by a short or transient sharp pain arising from exposed dentin. To treat DH, various desensitizers have been developed for occluding DTs. However, most desensitizers commercially available or in development are only able to seal the orifices, rather than the deep regions of the DTs, thus lacking long-term stability. Dr. C. Li, Prof. P. Yang found it is shown that the fast amyloid-like aggregation of lysozyme (lyso) conjugated with poly(ethylene glycol) (PEG) (lyso-PEG) can afford a robust ultrathin nanofilm on the deep walls of DTs through a rapid one-step aqueous coating process (in 2 min). The resultant nanofilm provides a highly effective antifouling platform for resisting the attachment of oral bacteria such as Streptococcus mutans and induces remineralization in the DTs to seal both the orifices and depths of the DTs by forming hydroxyapatite (HAp) minerals in situ. Both in vitro and in vivo animal experiments prove that the nanofilm-coated DTs are occluded with a depth of over 60 ± 5 µm, which is at least 6 times deeper than that reported in the literature. This approach thus demonstrates the concept that an amyloid-like proteinaceous nanofilm can offer an inexpensive, rapid, and efficient therapy for treating DH with long-term effect. Sinopeg provide various NW poly(ethylene glycol) (PEG) products: 2KDa, 5KDa, 10KDa, 20KDa, etc. Products: Linear Monofunctional PEGs Linear Bifunctional PEGs Linear Heterofunctional PEGs Branched PEGs Multi-Arm Functional PEGs Functionally Grafted PEGs
    View More
  • SINOPEG Gained Substantial Achievement in CPhI Worldwide 2019
    SINOPEG Gained Substantial Achievement in CPhI Worldwide 2019 2019-11-20
    CPhI Worldwide 2019 was held successfully in Frankfurt, Germany from Nov. 5th-7th. SINOPEG's CEO Dr. Wengui Weng and sales manager Mr. Lingnan Chen attended this exhibition. Our booth Number is 41K60. We SINOPEG was established in 2011, and specilized in PEG derivatives, PEG block-copolymer, side chain of diabetes medications etc.. We are not only maintain the advantage of old products, but also continue to work on the development of new products.   During the exhibition, many customers visited our booth. We had very deep discusstion with our old customers and partners regarding some issues and problems of ongoing projects, and reached agreements for the further programs. Besides, we also received many new potential customers from all over the world. They showed great interest in our products, and made preliminary cooperation intention with us. Thanks very much for the support and trust from all friends, customers and partners! We hope we can have close cooperation together, and reach win-win achievement in the future.
    View More
  • Tetra-PEG Based Hydrogel Sealants for In Vivo Visceral  Hemostasis
    Tetra-PEG Based Hydrogel Sealants for In Vivo Visceral Hemostasis 2019-11-08
    Tetra-PEG hydrogels based on the ammonolysis reaction between tetra-armed poly(ethylene glycol) amine (Tetra-PEG-NH2) and Tetra-PEG-SAE offer massive advantages as sealants. They are entirely synthetic without the misgivings of being inhibited by anticoagulation agents and transferring disease. Their cost is low due to their easily preservable components with high accessibility. Because of the intrinsic properties of this ammonolysis reaction, the resulting hydrogels can gel  fast just by injection and adhere to the tissues tightly throughchemical bonds. Another remarkable advantage for Tetra-PEG hydrogels is that they are mechanically tough, and the sealants are favored to be mechanically tough to keep stable in case of dynamic movement of the tissues and the use of assistant pressure which is a key adjunctive step in achieving hemostasis. However, two hurdles are preventing extending their applications in vivo. The first one is that just as commercialized sealants, none of the reported Tetra-PEG hydrogels could be controllably removed without mechanical debridement, which is extremely dangerous because of their high mechanical strength. Besides, they possess long degradation time, which will lead to severe foreign body reactions, tissue adhesion, disturbed tissue healing, and obstruction of the circulatory system, when used in vivo. Here, to overcome the limitations of the existing ammonolysis based Tetra-PEG hydrogels, we construct an optimized one (SS) with fast degradable and controllably dissolvable properties via Tetra-PEG-NH2 and tetra-armed poly(ethylene glycol) succinimidyl succinate (Tetra-PEG-SS) . The resulting SS exhibits biocompatibility superior to the reported degradable Tetra-PEG hydrogel (SG) based on Tetra-PEG-NH2 and tetra-armed poly(ethylene glycol) succinimidyl glutarate (Tetra-PEG-SG) . More importantly, in contrast to the disappointing results of SG that leads to serious adverse effects in in vivo hemostasis due to the long retention, SS causes almost no noticeable side effects with outstanding hemostasis efficacy even under the anticoagulated situations. This hydrogel is a promising candidate for the next-generation in vivo sealants in the aged society.
    View More
  • Visit SINOPEG at 2019 CPhI Worldwide, Germany
  • SINOPEG achieved so much in CPhI China 2019
    SINOPEG achieved so much in CPhI China 2019 2019-06-23
    CPhI China 2019 was held successfully in Shanghai, China from June 18th-20th. We Sinopeg sent a very professional sales team to participate this exhibition. Our booth Number is W4F21. During the exhibition, we had very deep disscuion with old partner, and customers from all over the world came to  consult the company's products,we obtained the approval and praise from our customers. Looking forward to see you again next year, CPhI China 2020 in Shanghai.
    View More
  • SINOPEG exhibits at 2019 API China (May 8 - May 10,2019)
    SINOPEG exhibits at 2019 API China (May 8 - May 10,2019) 2019-03-03
    Warmly welcome you to visit our booth 1D73 in API  (Hangzhou) from May. 8th to May. 10th, 2019. Exhibition name: the 82nd API China- China international pharmaceutical raw materials, intermediates, packaging, equipment fair. Booth number:1D73 Time: May 8-10,2019 Venue: Hangzhou international expo center We provided a wealth of polyethylene glycol derivatives, side chains of hypoglycemic drugs (Semaglutide side chain, Liraglutide side chain, Insulin Detemir side chain, Insulin Deglutide chain), polyethylene glycol block copolymers, polyethylene glycol phospholipids, etc. Welcome to our booth.
    View More
  • SINOPEG were certified ISO 13485 system qualification in August 2015.
  • SINOPEG were certified ISO-9001 quality management system qualification in November 2014.
first page 1 2 3 4 last page

A total of 4 pages

Copyright © XIAMEN SINOPEG BIOTECH CO., LTD. All Rights Reserved.